Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 3/20 | 0.35 |
| ▸ | OGA | O60502 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.34 |
| ▸ | PDE8B | O95263 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1687202 | 0.89 | NPC1 (0.38) | MAPK8MAPK10NPC1RAB9AKDM4E | |
| SCHEMBL15133278 | 0.80 | KDM4E (0.49) | KDM4EGPR119MAPT | |
| SCHEMBL1621687 | 0.76 | MAPT (0.47) | NPC1RAB9AKDM4EOGATAAR1 | |
| SCHEMBL22849709 | 0.74 | ALDH1A1 (0.43) | TP53 | |
| SCHEMBL11957018 | 0.72 | GPR119 (0.46) | NPC1RAB9AKDM4EOGAGPR119 | |
| SCHEMBL19450729 | 0.71 | OGA (0.47) | NPC1RAB9AKDM4EOGAGPR119 | |
| SCHEMBL18637545 | 0.71 | GPR119 (0.41) | MAPK8MAPK10OGAGPR119 | |
| SCHEMBL18637846 | 0.71 | MAPK8 (0.40) | MAPK8MAPK10ACACB | |
| SCHEMBL12239174 | 0.70 | TSHR (0.50) | NPC1RAB9AKDM4EOGAGPR119 | |
| SCHEMBL1103982 | 0.70 | MAPK8 (0.47) | MAPK8MAPK10NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362251-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2017-12-21 | — | — | US | disclosed |
| US-9725461-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150203509-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2015-07-23 | — | — | US | disclosed |
| US-8906909-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140155595-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8461157-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. | 2013-04-25 | — | — | US | disclosed |
| US-8367663-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20100222343-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155595-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | MAPK8 494/4885MAPK10 795/4885NPC1 2404/4885 |
| US-20170362251-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | MAPK8 494/4885MAPK10 795/4885NPC1 2404/4885 |
| US-20100222343-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | MAPK8 502/4885MAPK10 820/4885NPC1 2478/4885 |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | MAPK8 494/4885MAPK10 795/4885NPC1 2404/4885 |
| US-20150203509-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | MAPK8 502/4885MAPK10 820/4885NPC1 2478/4885 |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | KRAS, HRAS, KSR2 | MAPK8 664/4885MAPK10 555/4885NPC1 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.